The Radiochemistry and Molecular Imaging Probes (RMIP) Core Facility functions at the Intersection of the Cancer Center's laboratory research and clinical molecular Imaging initiatives - including cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology and engineering, and is the largest manufacturing unit at MSKCC in terms of the number of clinical and research products produced. The RMIP Core Facility was established to provide investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations. The RMIP Core Facility consists of three major elements working closely together to provide the following services: (a) The Cyclotron Unit. Our MSKCC EBCO cyclotron on 72nd street produces 18F, 1241, 86Y and 89Zr, positron emitting radionuclides for research and clinical applications;(b) The Small Molecule Radiochemistry Section. This section incorporates cyclotron-produced positron-emitting radionuclides into radiochemicals and radiopharmaceuticals;(c) The Antibody Labeling Section. This section is responsible for the radiolabeling of peptides and monoclonal antibodies as requested by preclinical and clinical investigators for both cancer diagnostic and therapeutic purposes. MSKCC and the RMIP Core Facility have an outstanding reputation as a center for clinical translation of both imaging and therapeutic agents. Specifically, with regard to the translation of radiopharmaceuticals, over the past 20 years, the RMIP Core Facility has translated 37 radiopharmaceuticals for research clinical trials (imaging and therapy) in humans with radiolabeled antibodies, small molecules, nanoparticles and radiotherapeutics. To meet the growing programmatic demands and new federal regulations, MSKCC has implemented a significant investment In our radiochemistry facilities (to include GMP environments) over the next five years. The services provided by the RMIP Core have supported the research of 26 investigators in the past year. During the past grant period the work of the Core has contributed to 174 publications of researchers from 5 research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933547
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$357,996
Indirect Cost
$156,535
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Basaraba, Cale N; Westhoff, Carolyn L; Pike, Malcolm C et al. (2017) Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception 95:398-404
Hernandez, Jonathan M; Beylergil, Volkan; Goldman, Debra A et al. (2017) Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg :
Argani, Pedram; Kao, Yu-Chien; Zhang, Lei et al. (2017) Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues. Am J Surg Pathol 41:1702-1712
Moore, Kathleen N; Martin, Lainie P; O'Malley, David M et al. (2017) Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35:1112-1118
Lee, Ser Yee; Goh, Brian K P; Sadot, Eran et al. (2017) Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol 24:202-210
Hyman, David M; Taylor, Barry S; Baselga, José (2017) Implementing Genome-Driven Oncology. Cell 168:584-599
Li, Gang G; Somwar, Romel; Joseph, James et al. (2017) Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clin Cancer Res 23:2981-2990
Bhagat, Tushar D; Zou, Yiyu; Huang, Shizheng et al. (2017) Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. J Biol Chem 292:837-846
Prieto-Granada, Carlos N; Zhang, Lei; Antonescu, Cristina R et al. (2017) Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature. J Cutan Pathol 44:201-209
He, Mu; Agbu, Stephanie; Anderson, Kathryn V (2017) Microtubule Motors Drive Hedgehog Signaling in Primary Cilia. Trends Cell Biol 27:110-125

Showing the most recent 10 out of 7561 publications